2/10
08:27 am
coya
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial [Yahoo! Finance]
Low
Report
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial [Yahoo! Finance]
2/10
08:00 am
coya
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
Low
Report
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial
2/2
08:05 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
1/31
08:44 am
coya
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement [Yahoo! Finance]
Medium
Report
Coya Therapeutics to sell 2.522M shares at $4.40 in private placement [Yahoo! Finance]
1/30
08:47 am
coya
Coya Therapeutics Announces $11.1 Million Private Placement [Yahoo! Finance]
Low
Report
Coya Therapeutics Announces $11.1 Million Private Placement [Yahoo! Finance]
1/30
08:00 am
coya
Coya Therapeutics Announces $11.1 Million Private Placement
Neutral
Report
Coya Therapeutics Announces $11.1 Million Private Placement
1/21
08:00 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/20
08:00 am
coya
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
Medium
Report
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders
1/8
05:14 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
1/8
08:00 am
coya
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
Low
Report
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
1/5
08:33 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
1/5
08:00 am
coya
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
Medium
Report
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
12/23
08:57 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Medium
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
12/23
08:37 am
coya
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
Medium
Report
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) [Yahoo! Finance]
12/23
08:00 am
coya
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Low
Report
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
12/9
09:39 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $15.00 price target on the stock.
12/9
08:00 am
coya
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
Low
Report
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
11/25
08:45 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences [Yahoo! Finance]
11/25
08:00 am
coya
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
Low
Report
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
11/25
08:00 am
coya
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
Low
Report
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
11/24
07:02 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/15
01:42 am
coya
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
Medium
Report
Coya Therapeutics (NASDAQ:COYA) was upgraded by analysts at
Wall Street
11/14
08:26 am
coya
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $14.00 price target on the stock.
11/13
01:39 pm
coya
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.
Low
Report
Coya Therapeutics (NASDAQ:COYA) had its price target raised by analysts at BTIG Research from $15.00 to $16.00. They now have a "buy" rating on the stock.